Regeneron Pharmaceuticals REGN Finance Lease Liabilities
Finance Lease Liabilities at other companies
Other financials
Where this comes from
Reported directly by Regeneron Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:FinanceLeaseLiabilityNoncurrent.
The official record: Regeneron Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Regeneron Pharmaceuticals's finance lease liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Regeneron Pharmaceuticals's finance lease liabilities?
- Regeneron Pharmaceuticals (REGN) reported finance lease liabilities of $0 in Q1 2026.
- How has Regeneron Pharmaceuticals's finance lease liabilities changed year-over-year?
- Regeneron Pharmaceuticals's finance lease liabilities decreased by 100.0% year-over-year, from $720M to $0.
- What is the long-term trend for Regeneron Pharmaceuticals's finance lease liabilities?
- Over 5 years (2020 to 2025), Regeneron Pharmaceuticals's finance lease liabilities has grown at a 0.1% compound annual growth rate (CAGR), from $717.2M to $720M.
- What does finance lease liabilities mean?
- Present value of future payments on leases classified as finance leases under ASC 842 — treated similarly to debt on the balance sheet.